Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M.

J Clin Invest. 2018 Sep 10. pii: 99317. doi: 10.1172/JCI99317. [Epub ahead of print]

2.

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.

Bastin D, Aitken AS, Pelin A, Pikor LA, Crupi MJF, Huh MS, Bourgeois-Daigneault MC, Bell JC, Ilkow CS.

J Immunother Cancer. 2018 Jun 19;6(1):62. doi: 10.1186/s40425-018-0366-2.

3.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
4.

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.

Aitken AS, Roy DG, Martin NT, Sad S, Bell JC, Bourgeois-Daigneault MC.

J Immunother. 2018 Apr;41(3):125-129. doi: 10.1097/CJI.0000000000000208.

5.

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM.

Cancer Res. 2018 Feb 15;78(4):922-937. doi: 10.1158/0008-5472.CAN-15-3308. Epub 2017 Dec 19.

PMID:
29259007
6.

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

Aitken AS, Roy DG, Bourgeois-Daigneault MC.

Biomedicines. 2017 Jan 4;5(1). pii: E3. doi: 10.3390/biomedicines5010003. Review.

7.

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault MC, Bell JC, Jäger D, von Kalle C, Ungerechts G, Engeland CE.

Oncoimmunology. 2017 Jan 31;6(4):e1285992. doi: 10.1080/2162402X.2017.1285992. eCollection 2017.

8.

MARCH1 E3 Ubiquitin Ligase Dampens the Innate Inflammatory Response by Modulating Monocyte Functions in Mice.

Galbas T, Raymond M, Sabourin A, Bourgeois-Daigneault MC, Guimont-Desrochers F, Yun TJ, Cailhier JF, Ishido S, Lesage S, Cheong C, Thibodeau J.

J Immunol. 2017 Jan 15;198(2):852-861. doi: 10.4049/jimmunol.1601168. Epub 2016 Dec 9.

9.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

10.

MARCH1 regulates insulin sensitivity by controlling cell surface insulin receptor levels.

Nagarajan A, Petersen MC, Nasiri AR, Butrico G, Fung A, Ruan HB, Kursawe R, Caprio S, Thibodeau J, Bourgeois-Daigneault MC, Sun L, Gao G, Bhanot S, Jurczak MJ, Green MR, Shulman GI, Wajapeyee N.

Nat Commun. 2016 Aug 31;7:12639. doi: 10.1038/ncomms12639.

11.

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.

Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo JS, Bell JC.

Breast Cancer Res. 2016 Aug 8;18(1):83. doi: 10.1186/s13058-016-0744-y.

12.

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.

Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC.

Mol Ther Oncolytics. 2016 Feb 17;3:16001. doi: 10.1038/mto.2016.1. eCollection 2016.

13.

Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Falls T, Roy DG, Bell JC, Bourgeois-Daigneault MC.

ILAR J. 2016;57(1):73-85. doi: 10.1093/ilar/ilv048.

14.

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA, Stojdl DF, Lichty BD, Atkins H, Auer RC, Bell JC, Le Boeuf F.

J Control Release. 2015 Dec 28;220(Pt A):210-221. doi: 10.1016/j.jconrel.2015.10.030. Epub 2015 Oct 19.

PMID:
26482080
15.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

16.

Tollip-induced down-regulation of MARCH1.

Bourgeois-Daigneault MC, Pezeshki AM, Galbas T, Houde M, Baril M, Früh K, Amrani A, Ishido S, Lamarre D, Thibodeau J.

Results Immunol. 2013 Feb 20;3:17-25. doi: 10.1016/j.rinim.2013.02.002. eCollection 2013.

17.

Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase.

Bourgeois-Daigneault MC, Thibodeau J.

J Cell Sci. 2013 Feb 15;126(Pt 4):989-98. doi: 10.1242/jcs.117804. Epub 2012 Dec 21.

18.

Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane.

Finzi A, Perlman M, Bourgeois-Daigneault MC, Thibodeau J, Cohen ÉA.

Cell Microbiol. 2013 May;15(5):809-22. doi: 10.1111/cmi.12074. Epub 2012 Dec 12.

19.

Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Thibodeau J, Bourgeois-Daigneault MC, Lapointe R.

Oncoimmunology. 2012 Sep 1;1(6):908-916.

20.

Autoregulation of MARCH1 expression by dimerization and autoubiquitination.

Bourgeois-Daigneault MC, Thibodeau J.

J Immunol. 2012 May 15;188(10):4959-70. doi: 10.4049/jimmunol.1102708. Epub 2012 Apr 16.

21.

Cutting edge: HLA-DO impairs the incorporation of HLA-DM into exosomes.

Xiu F, Côté MH, Bourgeois-Daigneault MC, Brunet A, Gauvreau MÉ, Shaw A, Thibodeau J.

J Immunol. 2011 Aug 15;187(4):1547-51. doi: 10.4049/jimmunol.1100199. Epub 2011 Jul 18.

22.

Sorting of MHC class II molecules into exosomes through a ubiquitin-independent pathway.

Gauvreau ME, Côté MH, Bourgeois-Daigneault MC, Rivard LD, Xiu F, Brunet A, Shaw A, Steimle V, Thibodeau J.

Traffic. 2009 Oct;10(10):1518-27. doi: 10.1111/j.1600-0854.2009.00948.x. Epub 2009 May 27.

23.

Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes.

Thibodeau J, Bourgeois-Daigneault MC, Huppé G, Tremblay J, Aumont A, Houde M, Bartee E, Brunet A, Gauvreau ME, de Gassart A, Gatti E, Baril M, Cloutier M, Bontron S, Früh K, Lamarre D, Steimle V.

Eur J Immunol. 2008 May;38(5):1225-30. doi: 10.1002/eji.200737902.

Supplemental Content

Loading ...
Support Center